# ADR 511 — Enterprise Biotechnology Biomedical Manufacturing Intelligence Platform (P217-L)

## Status

Accepted

## Context

P217-K established drug discovery intelligence. P217-L defines Biomedical Manufacturing Intelligence: Smart Bio Factory, Bio-POS, biopharmaceutical production domains, manufacturing digital twins, quality intelligence and GMP governance — before Supply Chain (P217-M).

## Decision

1. SoR remains `biotechnology` / `CAP-PLT-BIO-001` for manufacturing *intelligence* — never pharmacy dispense/EMR/LIMS SoR.
2. Fabric: `meos_bio_manufacturing_intelligence_fabric`.
3. API: `/api/v1/biotechnology/bio-manufacturing*`.
4. Six smart-factory layers; Bio-POS, biopharma domains, automation and manufacturing AI catalogs.
5. All inference via P214-Z ACL only — `no_module_local_llm`.
6. GMP compliance and human manufacturing oversight mandatory; never autonomous release without quality approval.
7. Robotics via P216-Z ACL; twins via P217-G; product intelligence via P217-K; quantum via P215-Z.
8. Never replace Core, AI, Quantum, Robotics, hospital EMR, LIMS, pharmacy, prior P217 fabrics including Drug Discovery.
9. Foundation for P217-M.

## Consequences

Positive: governed manufacturing layer for supply-chain and regulatory phases.  
Negative: OT security / batch traceability catalogs must stay aligned as autonomous production deepens.

## Alternatives rejected

- Sibling `bio_manufacturing` BC owning pharmacy or MES SoR outside biotechnology fabric.
- Module-local LLM or releasing batches without quality/GMP workflow.
- Merging laboratory LIMS operational SoR into biotechnology.

## Related

Law: `ENTERPRISE_BIOTECHNOLOGY_BIO_MANUFACTURING.md` · Prior: ADR 499–510 · Next: P217-M
